MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2022 International Congress

    Insights from skin biopsies: α-synuclein real-time quaking-induced conversion (RT-QuIC) in patients with Parkinson’s disease and multiple system atrophy

    C. Panzer, J. Volkmann, C. Sommer, K. Doppler, A. Kuzkina (Würzburg, Germany)

    Objective: To characterize skin alpha-synuclein (α-syn) pathology in synucleinopathies as a potential tool for differential diagnosis. Background: Differential diagnosis of PD and MSA represents a…
  • 2022 International Congress

    No evidence for the impact of SNCA rs356219 on Parkinson’s disease progression

    A. Szwedo, T. Stoker, M. Camacho, D. Backström, L. Forsgren, R. Lawson, A. Yarnall, C. Williams-Gray, A. Macleod, C. Counsell, OB. Tysnes, G. Alves, J. Maple-Grødem (Stavanger, Norway)

    Objective: To replicate findings from previous studies reporting an association between the α-synuclein (SNCA) rs356219 genetic variant and progression to key outcomes in Parkinson’s disease…
  • 2022 International Congress

    The anti-alpha-synuclein antibody Lu AF82422 was safe and well tolerated in a FIH-SAD study in healthy subjects and patients with PD

    L. Buur, J. Wiedemann, F. Larsen, F. Ben Alaya-Fourati, P. Kallunki, D. Ditlevsen, M. Sørensen, D. Meulien (Valby, Denmark)

    Objective: Evaluation of safety, tolerability, pharmacokinetics (PK) and target engagement (TE) in healthy subjects (HS) and patients with Parkinson’s disease (PD) following single ascending doses…
  • 2022 International Congress

    Can membrane association of α-synuclein aggregates lead to stress in the astrocytic endoplasmic reticulum?

    A. Raj, I. Datta, R. Banerjee (Bangalore, India)

    Objective: To study the association extracellularly added wildtype-WT and A30P/A53T mutant α-synuclein aggregates with the astrocytic membrane and to evaluate the effect of these peptides…
  • 2022 International Congress

    The overexpression of a-SYN leads to a differential process of mitophagy in neurons and atrocytes

    I. Lastres-Becker, S. Castro-Sánchez, I. Silva-Llanes, P. Teresak, JL. Lanciego, E. Sierra, P. Boya (Madrid, Spain)

    Objective: To determine the role of the different mitophagy pathways involved in PD, a key question that is still unresolved. We will investigate whether a-synuclein…
  • 2022 International Congress

    Early Synucleinopathy is Associated with Differential Regulation of Neurotransmission and Immune Related Genes

    J. Patterson, J. Kochmanski, A. Stoll, M. Kubik, C. Kemp, J. Howe, M. Duffy, K. Miller, A. Cole-Strauss, J. Beck, S. Counts, K. Steece-Collier, A. Bernstein, K. Luk, C. Sortwell (Grand Rapids, USA)

    Objective: Identification of gene expression changes in the rat substantia nigra pars compacta (SNpc) associated with early alpha-synuclein (a-syn) inclusion formation. Background: Accumulation of intracellular…
  • 2022 International Congress

    Evaluation of α-synuclein pathology and function in dopaminergic neurons derived from LRRK2 I1371V PD patient iPSCs

    I. Datta, S. Jagtap, C. Potdar (Bangalore, India)

    Objective: To evaluate cellular pathogenesis in DA neuron function, and α-synuclein pathology using LRRK2-I1371V PD iPSC. Background: It is reported for complex-neurodegenerative disorders like PD,…
  • 2022 International Congress

    A mouse model to test the cortical pathogenic theory of Parkinson’s disease

    M. Moreno-Gómez, D. Humanes-Valera, J. Pardo-Valencia, N. Mercado-García, B. Pro-Sánchez, A. Revuelto-González, T. Balzano, J. Blesa, A. Bortolozzi, J A. Obeso, G. Foffani (Móstoles, Spain)

    Objective: To develop a mouse model of chronic corticostriatal overactivity and increase expression of corticostriatal alpha-synuclein. Background: Parkinson’s disease typically has a focal motor onset1,…
  • 2022 International Congress

    The anti-alpha-synuclein antibody Lu AF82422 binds to pathological alpha-synuclein species from human brains and inhibits seeded alpha-synuclein aggregation

    P. Kallunki, K. Willén, F. Sotty, L. Buur, K. Bjerregaard-Andersen, M. Lubas, D. Damlund, M. Harndahl, K. Fog (Valby, Denmark)

    Objective: Lu AF82422 is a human IgG1 monoclonal antibody that binds all known forms of alpha-synuclein (aSyn), including monomeric, aggregated and truncated. Data are presented…
  • 2022 International Congress

    Gray matter volume of proposed brain-first and body-first Parkinson’s disease subtypes

    M. Banwinkler, V. Dzialas, M. Hoenig, T. van Eimeren (Cologne, Germany)

    Objective: The aim of this study was to test if markers of the brain-first Parkinson’s disease (PD) subtype are associated with a greater or more…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 51
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley